Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry
| العنوان: | Impact of lenalidomide-bortezomib-dexamethasone (RVd) induction on patients with newly diagnosed multiple myeloma and renal impairment: Results from the Connect MM Registry |
|---|---|
| المؤلفون: | Suzanne Robinson, Robert M. Rifkin, Howard R. Terebelo, Shankar Srinivasan, Kathleen Toomey, Mohit Narang, Hans C. Lee, Mia He, James W. Hardin, Lynne I. Wagner, Mazaher Dhalla, Prashant Joshi, Jim Omel, Brian G.M. Durie, Sundar Jagannath, Rafat Abonour, Sikander Ailawadhi, Cristina Gasparetto |
| المصدر: | Web of Science |
| بيانات النشر: | American Society of Clinical Oncology (ASCO), 2020. |
| سنة النشر: | 2020 |
| مصطلحات موضوعية: | Oncology, Cancer Research, medicine.medical_specialty, business.industry, macromolecular substances, Newly diagnosed, medicine.disease, carbohydrates (lipids), Clinical trial, stomatognathic diseases, Internal medicine, otorhinolaryngologic diseases, Medicine, business, INDUCTION TREATMENT, Multiple myeloma, Bortezomib/dexamethasone, Lenalidomide, medicine.drug |
| الوصف: | 8518 Background: Patients (pts) with newly diagnosed multiple myeloma (NDMM) and renal impairment (RI) are often excluded from clinical trials. Data are limited on the effects of induction treatment in these pts, who may also be ineligible for autologous stem cell transplant (SCT) due to severity of RI. This analysis investigated the impact of RVd induction on renal function in transplant eligible (TE) and noneligible (TNE) pts from the Connect MM Registry, a US, multicenter, prospective, observational study. Methods: Eligible pts were ≥ 18 y and had symptomatic MM diagnosed ≤ 2 mos prior to enrollment, as defined by the International Myeloma Working Group criteria. For this analysis, pts that received front-line RVd for ≥ 3 cycles were grouped per transplant eligibility and renal function at baseline (BL; creatinine clearance [CrCl] < 30, 30-50, > 50-80, and > 80). Pts with progressive disease at BL were excluded. Renal function at 3 mos was measured. Median unadjusted progression-free survival (PFS) was calculated from start of regimen in TE and TNE populations, with pts grouped by CrCl (≤ 60 or > 60) at BL. Results: As of 7/23/19, 421 TE and 212 TNE pts received RVd for ≥ 3 cycles. TE and TNE pts were grouped by BL CrCl of < 30 (20 and 16 pts), 30-50 (36 and 50 pts), > 50-80 (117 and 63 pts), and > 80 (248 and 83 pts). Renal function improvement was observed in all pts receiving RVd, including those with moderate (30-50 CrCl) and severe (< 30 CrCl) RI at BL (Table). In pts with > 60 CrCl and ≤ 60 CrCl at BL, median PFS in TE pts was 48.6 mos and 43.2 mos, respectively. In TNE pts, median PFS was 36.4 mos and 30.6 mos, respectively. Conclusions: The results from the Connect MM Registry indicate that pts with NDMM and RI (including moderate and severe) who receive front-line RVd for ≥ 3 cycles may see improvement in renal function at 3 mos, regardless of transplant eligibility. RVd therefore can potentially be used in pts with RI. This analysis provides real-world data that support further investigation of RVd treatment in pts with moderate or severe RI. Clinical trial information: NCT01081028 . [Table: see text] |
| تدمد: | 1527-7755 0732-183X |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e21fad74dc6a150b17cb01cff5d14f0b https://doi.org/10.1200/jco.2020.38.15_suppl.8518 |
| رقم الأكسشن: | edsair.doi.dedup.....e21fad74dc6a150b17cb01cff5d14f0b |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15277755 0732183X |
|---|